Trial intelligence / Profile preview

Bimekizumab in early-onset versus long-duration plaque psoriasis

jRCTs041260166

Key facts

Status
Recruiting
Start
Nov 2026
Countries
1
Sponsor
UCB
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Conditions
plaque psoriasis
01

Overview

Open-label, single-arm trial of bimekizumab in plaque psoriasis, sponsored by UCB. Primary endpoint: PASI 100 achievement rate at week 16. Started Nov 2026; status: recruiting.

02

Design

1 arm
Study design
Non-randomizedOpen-labelSingle group
  • Single treatment cohort

    All participants receive bimekizumab initially, with post-week-16 branching based on PASI 100 achievement.

03

Who it enrols

Adults with plaque psoriasis requiring biologic-level treatment are eligible if disease duration is either less than 2 years or more than 10 years and they have inadequate response to existing systemic therapy/phototherapy with body surface area involvement of at least 10%, or DLQI greater than 10, or refractory lesions in difficult areas with PASI of at least 5. Patients with clinically significant active psoriatic arthritis needing treatment escalation, severe infection, active tuberculosis, pregnancy, recent interventional trial participation, or extensive prior biologic exposure are…

04

Endpoints

Primary

  • PASI 100 achievement rate at week 16

Secondary

  • Remission maintenance period and maintenance rate after discontinuation

  • Change over time in psoriasis severity and quality-of-life indices

  • Changes in concomitant medication use

  • Serum chemokine and cytokine exploratory analyses

  • Skin biopsy exploratory analyses

Beyond the preview

Go deeper on jRCTs041260166.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on jRCTs041260166.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call